Los Angeles Capital Management LLC Sells 26,543 Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC)

Los Angeles Capital Management LLC decreased its holdings in shares of Revance Therapeutics, Inc. (NASDAQ:RVNC) by 22.8% in the third quarter, Holdings Channel.com reports. The firm owned 89,825 shares of the biopharmaceutical company’s stock after selling 26,543 shares during the period. Los Angeles Capital Management LLC’s holdings in Revance Therapeutics were worth $466,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in RVNC. Capital World Investors increased its position in Revance Therapeutics by 16.8% during the 1st quarter. Capital World Investors now owns 13,945,535 shares of the biopharmaceutical company’s stock valued at $68,612,000 after buying an additional 2,006,459 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Revance Therapeutics by 6.5% during the first quarter. Vanguard Group Inc. now owns 5,398,406 shares of the biopharmaceutical company’s stock valued at $26,560,000 after acquiring an additional 328,781 shares in the last quarter. Stonepine Capital Management LLC raised its position in shares of Revance Therapeutics by 41.7% in the 2nd quarter. Stonepine Capital Management LLC now owns 2,800,000 shares of the biopharmaceutical company’s stock worth $7,196,000 after purchasing an additional 823,658 shares during the last quarter. Federated Hermes Inc. boosted its stake in Revance Therapeutics by 43.0% in the 2nd quarter. Federated Hermes Inc. now owns 2,237,505 shares of the biopharmaceutical company’s stock worth $5,750,000 after purchasing an additional 672,803 shares in the last quarter. Finally, Opaleye Management Inc. purchased a new stake in Revance Therapeutics during the 1st quarter valued at about $3,862,000. 97.70% of the stock is currently owned by hedge funds and other institutional investors.

Revance Therapeutics Trading Down 3.2 %

Shares of RVNC stock opened at $4.17 on Friday. The company has a 50 day simple moving average of $5.41 and a two-hundred day simple moving average of $4.44. The stock has a market cap of $437.43 million, a P/E ratio of -2.16 and a beta of 0.95. Revance Therapeutics, Inc. has a 12 month low of $2.30 and a 12 month high of $9.74.

Revance Therapeutics (NASDAQ:RVNC) last announced its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.02). The company had revenue of $59.88 million during the quarter, compared to the consensus estimate of $67.73 million. As a group, equities analysts forecast that Revance Therapeutics, Inc. will post -1.54 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have recently issued reports on RVNC shares. William Blair reiterated a “market perform” rating on shares of Revance Therapeutics in a research note on Monday, August 12th. HC Wainwright reiterated a “neutral” rating and set a $6.60 target price on shares of Revance Therapeutics in a research note on Friday, November 8th. Piper Sandler cut Revance Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 12th. Stifel Nicolaus dropped their price objective on Revance Therapeutics from $24.00 to $20.00 and set a “buy” rating on the stock in a research report on Friday, August 9th. Finally, Guggenheim reissued a “neutral” rating on shares of Revance Therapeutics in a research report on Monday, August 12th. Nine investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $9.66.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.